References
- Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on
the Primary Prevention of Cardiovascular Disease: A Report of the
American College of Cardiology/American Heart Association Task Force
on Clinical Practice Guidelines. Circulation. 2019;140(11):e596-e646.
- Frederix I, Dendale P, Schmid JP. Who needs secondary prevention?. Eur
J Prev Cardiol. 2017;24(3_suppl):8-13.
- Elmariah S, Rao SV, Grines CL, Garratt KN, Caputo RP, et al. How can
SCAI and industry partners increase adherence and educate
interventionalists on optimal medical therapy?. Catheter Cardiovasc
Interv. 2019;93(2):305-308.
- Nowbar AN, Gitto M, Howard JP, Francis DP, Al-Lamee R. Mortality From
Ischemic Heart Disease. Circ Cardiovasc Qual Outcomes. 2019
Jun;12(6):e005375.
- Du L, Cheng Z, Zhang Y, Li Y, Mei D. The impact of medication
adherence on clinical outcomes of coronary artery disease: A
meta-analysis. Eur J Prev Cardiol. 2017;24(9):962-970.
- Gibbons RJ, Miller TD. Optimal Medical Therapy for Known Coronary
Artery Disease: A Review. JAMA Cardiol. 2017;2(9):1030-1035.
- Chen ST, Huang ST, Shau WY, et al. Long-term statin adherence in
patients after hospital discharge for new onset of atherosclerotic
cardiovascular disease: a population-based study of real world
prescriptions in Taiwan. BMC Cardiovasc Disord. 2019;19(1):62.
- Hirsh BJ, Smilowitz NR, Rosenson RS, Fuster V, Sperling LS.
Utilization of and Adherence to Guideline-Recommended Lipid-Lowering
Therapy After Acute Coronary Syndrome: Opportunities for Improvement.
J Am Coll Cardiol. 2015;66(2):184-92.
- Rodriguez F, Maron DJ, Knowles JW, et al. Association of Statin
Adherence With Mortality in Patients With Atherosclerotic
Cardiovascular Disease. JAMA Cardiol. 2019;4(3):206-213.
- Sabatè E. Adherence to long-term therapies: Evidence for action: World
Health Organization. Towards the Solution. 2003. p.27-38.
- Bradley CK, Wang TY, Li S, et al. Patient-Reported Reasons for
Declining or Discontinuing Statin Therapy: Insights From the PALM
Registry. J Am Heart Assoc. 2019;8(7):e011765.
- Samaras K, Makkar SR, Crawford JD, et al. Effects of Statins on
Memory, Cognition, and Brain Volume in the Elderly. J Am Coll Cardiol.
2019;74(21):2554-2568.
- Abughosh SM, Vadhariya A, Johnson ML, et al. Enhancing Statin
Adherence Using a Motivational Interviewing Intervention and Past
Adherence Trajectories in Patients with Suboptimal Adherence. J Manag
Care Spec Pharm. 2019;25(10):1053-1062.
- Ahmed ST, Akeroyd JM, Mahtta D, et al. Shared Decisions: A Qualitative
Study on Clinician and Patient Perspectives on Statin Therapy and
Statin-Associated Side Effects. J Am Heart Assoc. 2020;9(22):e017915.
- Maningat P, Gordon BR, Breslow JL. How do we improve patient
compliance and adherence to long-term statin therapy? Curr Atheroscler
Rep. 2013;15(1):291.
- Muñoz D, Uzoije P, Reynolds C, et al. Polypill for Cardiovascular
Disease Prevention in an Underserved Population. N Engl J Med.
2019;381(12):1114-1123.
- Singh K, Crossan C, Laba TL, et al. Cost-effectiveness of a fixed dose
combination (polypill) in secondary prevention of cardiovascular
diseases in India: Within-trial cost-effectiveness analysis of the
UMPIRE trial. Int J Cardiol. 2018;262:71-78.
- Jowett S, Barton P, Roalfe A, et al. Cost-effectiveness analysis of
use of a polypill versus usual care or best practice for primary
prevention in people at high risk of cardiovascular disease. PLoS One.
2017;12(9):e0182625.
- Franczyk B, Gluba-Brzózka A, Jurkiewicz L, et al. Embracing the
polypill as a cardiovascular therapeutic: is this the best strategy?
Expert Opin Pharmacother. 2018;19(17):1857-1865.
- Sukonthasarn A, Chia YC, Wang JG, et al. The feasibility of polypill
for cardiovascular disease prevention in Asian Population. J Clin
Hypertens (Greenwich). 2021;23(3):545-555.
- López-Jaramillo P, González-Gómez S, Zarate-Bernal D, et al. Polypill:
an affordable strategy for cardiovascular disease prevention in
low-medium-income countries. Ther Adv Cardiovasc Dis.
2018;12(6):169-174.
- Ferket BS, Hunink MG, Khanji M, et al. Cost-effectiveness of the
polypill versus risk assessment for prevention of cardiovascular
disease. Heart. 2017;103(7):483-491.
- Cordero A, Rodriguez Padial L, Batalla A, et al. Optimal
pharmacological treatment and adherence to medication in secondary
prevention of cardiovascular events in Spain: Results from the CAPS
study. Cardiovasc Ther. 2017;35(2).
- Khunti K, Danese MD, Kutikova L, et al. Association of a Combined
Measure of Adherence and Treatment Intensity With Cardiovascular
Outcomes in Patients With Atherosclerosis or Other Cardiovascular Risk
Factors Treated With Statins and/or Ezetimibe. JAMA Netw Open.
2018;1(8):e185554.
- Ramsaran E, Preusse P, Sundaresan D, et al. Adherence to Blood
Cholesterol Treatment Guidelines Among Physicians Managing Patients
With Atherosclerotic Cardiovascular Disease. Am J Cardiol.
2019;124(2):169-175.
- Reston JT, Buelt A, Donahue MP, et al. Interventions to Improve Statin
Tolerance and Adherence in Patients at Risk for Cardiovascular Disease
: A Systematic Review for the 2020 U.S. Department of Veterans Affairs
and U.S. Department of Defense Guidelines for Management of
Dyslipidemia. Ann Intern Med. 2020;173(10):806-812.
- Ahmed ST, Mahtta D, Rehman H, et al. Association between frequency of
primary care provider visits and evidence-based statin prescribing and
statin adherence: Findings from the Veterans Affairs system. Am Heart
J. 2020;221:9-18.
- Rehman H, Ahmed ST, Akeroyd J, et al. Relation Between Cardiology
Follow-Up Visits, Evidence-Based Statin Prescribing, and Statin
Adherence (from the Veterans Affairs Health Care System). Am J
Cardiol. 2019;124(8):1165-1170.
- Shaw LJ, Berman DS, Maron DJ, et al. Optimal medical therapy with or
without percutaneous coronary intervention to reduce ischemic burden:
results from the Clinical Outcomes Utilizing Revascularization and
Aggressive Drug Evaluation (COURAGE) trial nuclear substudy.
Circulation. 2008;117(10):1283-91.
- De Bruyne B, Pijls NH, Kalesan B, Barbato E, Tonino PA. Fractional
flow reserve-guided PCI versus medical therapy in stable coronary
disease. N Engl J Med. 2012;367(11):991-1001.
- Khan AA, Khalid MF, Ayub MT, et al. Outcomes of Percutaneous Coronary
Intervention Versus Optimal Medical Treatment for Chronic Total
Occlusion: A Comprehensive Meta-analysis. Curr Probl Cardiol.
2021;46(3):100695.
- Morisky DE, Green LW, Levine DM. Concurrent and Predictive Validity of
a Self-Reported Measure of Medication Adherence and Long-Term
Predictive Validity of Blood Pressure Control. Medical Care 1986.
- Morisky DE, Malotte CK, Choi P, et al. A Patient Education Program to
Improve Rate with Antituberculosis Drug Regimens. Health Education
Quarterly 1990; 17:253-268
- Morisky DE, DiMatteo MR. Improving the measurement of self-reported
medication nonadherence: Final response. J Clin Epidemio 2011;
64(3):262-263.